Paper Details

  1. Home
  2. Paper Details

Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause: A Randomized Controlled Trial.

Author: CanoAntonio, EnglishMarci, FranklinCatherine, LedermanSamuel, NappiRossella E, Neal-PerryGenevieve, OtteryFaith D, SantoroNanette, ValluriUdaya, WolfmanWendy

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A 52-week safety study of fezolinetant in postmenopausal women seeking treatment for vasomotor symptoms found that fezolinetant was well-tolerated and had a low incidence of endometrial hyperplasia and malignancy.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To evaluate the safety, tolerability, and effect of fezolinetant on endometrial health over 52 weeks. METHODS: We conducted a phase 3, randomized, double-blind, 52-week safety study (SKYLIGHT 4 [Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026946/

データ提供：米国国立医学図書館（NLM）

Fezolinetant: A Beacon of Hope in the Desert of Menopause Symptoms

Menopause, a natural transition in a woman's life, can often be accompanied by uncomfortable symptoms, particularly vasomotor symptoms like hot flashes. This study investigates the safety and tolerability of fezolinetant, a novel medication designed to alleviate these symptoms. The researchers conducted a phase 3, randomized, double-blind, 52-week safety study to evaluate the long-term effects of fezolinetant in postmenopausal women experiencing vasomotor symptoms. The study revealed that fezolinetant was well-tolerated and did not increase the risk of endometrial hyperplasia or malignancy, supporting its continued development as a potential treatment for vasomotor symptoms associated with menopause.

Fezolinetant: A Beacon of Hope in the Desert of Menopause Symptoms

The study's findings provide reassuring data on the safety and tolerability of fezolinetant, offering hope for a new and effective treatment for vasomotor symptoms associated with menopause. The authors highlight the need for further research to confirm these findings and evaluate the long-term efficacy of fezolinetant in managing these symptoms.

Fezolinetant: A Beacon of Hope in the Desert of Menopause Symptoms

For women experiencing vasomotor symptoms associated with menopause, open communication with your healthcare provider is essential to discuss all available treatment options, including fezolinetant. This medication may offer a promising new approach to managing these symptoms, but it's important to discuss your individual needs and concerns with your doctor.

Dr. Camel's Conclusion

Menopause can feel like a desert of discomfort, but fezolinetant emerges as a potential oasis, offering relief from vasomotor symptoms and a smoother transition through this life stage. This study underscores the importance of ongoing research to develop safe and effective treatments for menopausal women, improving their quality of life during this significant period.

Date :
  1. Date Completed 2023-03-28
  2. Date Revised 2023-04-23
Further Info :

Pubmed ID

36897180

DOI: Digital Object Identifier

PMC10026946

Related Literature

Article Analysis
・Effects of fezolinetant
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.